Dr Sean C. McConnell provides an introduction to gene editing, and Scott J. Schweikart discusses what prudent governance requires.

Dr Esha Bansal joins Ethics Talk to discuss her article, coauthored with Drs Saran Kunaprayoon and Linda P. Zhang: “Opportunities for Global Health Diplomacy in Transnational Robotic Telesurgery.”

Dr Laura Kolbe joins Ethics Talk to discuss her article, coauthored with Drs Ryan H. Nelson, Joelle Robertson-Preidler, Olivia Schuman, and Inmaculada de Melo-Martín: “Is a Video Worth a Thousand Words?”

Teddie Bernard joins Ethics Talk to discuss their comic: Talking About Teletherapy.

Large precision health initiatives like the National Institutes of Health’s All of Us campaign raise important ethical questions about consent, privacy, and inclusivity. This month on Ethics Talk, we explore with Dr Katie Johansen Taber and Ysabel Duron strategies for protecting participants and ensuring that diverse communities are represented.

Dr Olivia Kates talks about appropriate use of antibiotics during the COVID-19 pandemic.

Direct-to-consumer genetic testing requires that physicians share decision making with patients, not order unnecessary tests or interventions, and refer to genetic specialists when necessary.

Mandatory genetic testing of health care professionals could help structure health care organizations’ responses to a pandemic. Patients and more susceptible employees can benefit, and these benefits must be weighed against concerns about fairness, autonomy, genetic privacy, and potential loss of employment opportunities.

Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.

Rare genetic disease research has something to teach precision medicine about addressing some patients’ limited access to treatment. Health disparities exacerbated by high costs and limited availability of drugs can, perhaps, be mitigated when patient activism accelerates drug development.